News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Islet Sciences Announces Positive 12-Week Phase 2 Clinical Results For SGLT2 Inhibitor Remogliflozin Etabonate


4/17/2014 9:22:48 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

RALEIGH, N.C., April 16, 2014 (GLOBE NEWSWIRE) -- Islet Sciences, Inc. (OTCQB:ISLT) and BHV Pharma today announced positive results from two 12-week phase 2b clinical studies of remogliflozin etabonate in type 2 diabetics. The primary end point was HbA1c with secondary end points of fasting plasma glucose, serum lipids, body weight, safety and tolerability. Remogliflozin etabonate is a selective SGLT2 inhibitor indicated for type 2 diabetes and NASH. Islet Sciences will present the full results of the two phase 2b clinical studies at the 74th American Diabetes Association Scientific Sessions in San Francisco, June 13-17th.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES